Yordanka Lambova, BSN, RRNA 2 Webster University Nurse Anesthesia Program.
-
Upload
virginia-wheeler -
Category
Documents
-
view
229 -
download
4
Transcript of Yordanka Lambova, BSN, RRNA 2 Webster University Nurse Anesthesia Program.
Methylene Blue and Catecholamine Nonresponsive Hypotension
Yordanka Lambova, BSN, RRNA 2Webster University Nurse Anesthesia Program
ObjectivesVasoplegic Syndrome
DefinitionRisk FactorsPathophysiology
Methylene Blue PharmacologyApplicationSide Effects Evidence Based Practice
Copyright ©1994 The American Association for Thoracic Surgery
Gomes W. J. et al.; J Thorac Cardiovasc Surg 1994;107:942-a-943-a
“Vasoplegic Syndrome”(VS) --Gomez (1994)—vasodilatory phenomenon refractory to high dose catecholamines in adult cardiac surgery1,2
Vasoplegic SyndromeObserved in all age groups and clinical settings
SepsisSystemic inflammatory response syndrome (SIRS)Cardiac surgeryAnaphylactic shock
Cardiac SurgeryHeparin and renin-angiotensin system (RAS)
antagonists are the only medications considered risk factor for VS3
Incidence with cardiac surgery is ranging from 0.21 to 13%, up to 50% when patients on RAS antagonists4
Mortality rate is 16 to 27%5,6,7
Vasoplegic SyndromeCommon Etiology Pathway
Endothelial injury and release of vasodilatory inflammatory mediatorsTumor necrosis factor
alpha (TNF-α) Interferon gamma (IFN-
γ) Interleukin-1 (IL-1)Atrial Natriuretic
Peptide (ANP)
Arginine-vasopressin system dysfunction and deficiency of vasopressin hormone
KATP channel activation in the plasma membrane
Inducible Nitric Oxide Synthase (iNOS) activation
•Nitric oxide (NO) production from L-arginine is catalyzed by a family of NO synthases (NOS)
•Endothelial NOS (eNOS) provides a basal release of NO to maintain smooth muscle vascular tone
•iNOS in heart, lungs, and vascular smooth muscle cells is up regulated by the influence of proinflammatory cytokines and/or endotoxin
•Large amount of NO is produced
•Soluble guanylate cyclase (sGC) is released
•Cyclic guanosine 3’-5’ monophosphate (cGMP) is generated
•Smooth muscle cell cGMP-mediated vasodilation and decrease myocyte contractility—relaxation of myocardial and vascular smooth muscle
What do I reach for with catecholamine nonresponsive hypotension?
•Persistent hypotension
•Tachycardia
•Normal or increased cardiac output
•Decreased systemic vascular resistance
•Low filling pressure
•Poor or no response to fluid resuscitation and vasopressors
Methylene Blue (MB)
Something Old, Something BluePrepared by Caro in 1876 as a dye for textiles
First fully synthetic drug used in medicine
1891 Paul Ehrlich identified the compound as an anti-malarial
1899 positive psychotropic effects observed (Potent, but reversible MAOI)
1933 used as an antidote to cyanide poisoning
Beginning of the 20th century MB used in a wide variety of medical, hygienic, and microbiology compounds
MB: Chemical Properties
Heterocyclic aromatic chemical compound
Chemical formula C16H18N3SCl
Melting temperature 180 degrees
Solubility in water 35.5 g/1
pH value—3 (10g/l H2O)
Solid, odorless, dark green powder at room temperature
Blue solution when dissolved in water or alcohol
Three molecules of MB per molecule of water
MB: Pharmacokinetics Oral absorption is between 53 to 97%
Completely ionized at gastric pH
Peak plasma concentration in 30-60 min
Volume of distribution 20 ml/kg
Plasma half-life 5-6 hrs
Metabolism reduced in peripheral tissues to leucomethylene blue (65-85%)
Does not bind to plasma proteins
Eliminated in bile, feces, and urine as leucomethylene blue
MB: Dosing in HumansSepsis9,10
1-2 mg/kg/10-20 min IV bolus 0.25-1 mg/kg/hr for 6hrs IV
continuous infusion
Anaphylactic shock11
1.5-2 mg/kg IV bolus
Hereditary methemoglobinemia Up to 300mg/day PO
Ifosfamide encephalopathy 50 mg three times a day PO12
Vasodilation with hypotension5,6
1-2 mg/kg/10-20 min IV bolus
VS8
1-2 mg/kg/10-20 min IV bolus 0.25-1 mg/kg/hr IV 48-72 hrs IV
continuous infusion
Surgery for septic endocarditis13, Cardiopulmonary bypass (CPB)5,11,14
2 mg/kg IV bolus prior to CPB 0.5 mg/kg/hr after bolus for 30
min after CPB
MB: Dose Related Toxicity
Human Studies StudiesDose mg/kg
Toxic Manifestations14,15
2-4 Hemolytic anemia, skin desquamation in infants
7 Nausea, vomiting, abdominal pain, chest pain, fever, hemolysis
7.5 Hyperpyrexia, confusion
20 Hypotension
80 Bluish discoloration of skin (similar to cyanosis)
Dose mg/kg
Animal Toxic Manifestations
5-50 Rat16 Neuronal apoptosis1250 mg/kg LD50
3500 Mouse
40 Sheep17
10-20 Dog18 Hypotension, decreased SVR, renal blood flow; pulmonary hypertension
MB: ContraindicationsGlucose-6-phosphate
dehydrogenase deficiency--may precipitate hemolytic anemia
Renal impairment—acceptable if on dialysis
Intrathecal and subcutaneous injection
Hypersensitivity and allergy to MB
Dapsone- forms hydroxylamine causing hemolysis
FDA recommendation-MB should not be given to patients taking serotonergic drugs. However, there are some conditions that may be life-threatening or require urgent treatment with MB such as methemoglobinemia, ifosfamide-induced encephalopathy, or cyanide poisoning.
MB: Mechanism of Action in VS
Direct inhibitory effect on NOS19,20
Blocks accumulation of cGMP by inhibiting the enzyme guanylate cyclase19
Blocks the activity of NO-dependent guanylate cyclase via oxidation of the active haemo center or by inactivation of its haemo center.19,20
More specific and potent inhibitor of NOS than guanylyl cyclase– NO-donating compounds in the presence of MB can still partially activate c-GMP signaling pathways21,22
Effects due to NO inhibition
MB restores vascular reactivity to endogenous catecholamines in the setting of excessive NO production23
Not a vasoconstrictor, rather it acts as a liberator of cAMP, thus allowing norepinephrine to exert its vasoconstrictive effect24
MB: Hepatic Failure Schenk et al (2000)25
Case Series (n=10) of hepatic cirrhosis and hepatopulmonary syndrome patients
Reports improvement of hypoxemia and hyperdynamic circulation evidenced by significant increase in PaO2, SVR; and decrease in MPAP, PVR, CO
MB 3 mg/kg IV over 15 minutes No significant side effects noted
Kalambokis (2005)26
Investigational study (n=20, 10 experimental group, 10 placebo group) on cirrhosis and ascites patients
MB 3 mg/kg IV No change in MAP, HR, CO, SVR; plasma renin, aldosterone, antidiuretic
hormone, urea, Cr, Na, GFR, Serum NO, and urinary Na decreased 4 hrs, but returned to basal levels in
8 hrs
Almeida et al (2007)27
Case report (n=1) on use of MB in hepatopulmonary syndrome Large right to left intrapulmonary shunt and subsequent improvement of
vascular tone and hyperdynamic circulation at the cost of worsening hypoxemia
MB: Renal Failure
Peer (2001)28
Investigational study (n=41, 18 HD/HoTN, 18 HD/no HoTN, 5 healthy controls)
MB IV bolus 1 mg/kg followed by infusion of 0.1 mg/kg for 210 minutes until completion of HD, bolus dose only on days without HD
Results HD/HoTN—completely prevented HoTN during HD, increased BP on
non HD days, blood NO measurements higher than other groups HD/no HoTN—increase of BP during first hour of HD, and 90 minutes
on non HD days. Healthy controls—no significant change in BP
MB: Sepsis Daemen-Gubbels et al (1995)29
Prospective observational (n=9) MB 2 mg/kg/20 min Increase in MAP, MPAP, LVSWI, RVSWI (p<0.01); increase in oxygen
delivery and uptake index (p<0.05) Mortality: 89%
Kirov et al (2001)9
Prospective, randomized, placebo controlled study (n=20, 10 MB treatment and 10 placebo isotonic saline)
MB 2 mg/kg/20min, 0.25 mg/kg/hr at 2hrs, 0.5 mg/kg/hr at 3hrs, 1 mg/kg/hr at 4 hrs, 2 mg/kg/hr at 5hrs for 1 hr
Improvement in hemodynamics and decrease in vasoconstrictors and inotropes (p<0.05)
Mortality: 5 patients vs. 7 in placebo group
Memmis et al (2002)30
prospective, randomized, double blind, placebo controlled (n=30, 15 MB and 15 placebo isotonic saline)
MB 0.5 mg/kg/hg 6 hrs MB group increase in MAP (p<0.001) Mortality: 27% in both cohorts
MB: Cardiac Surgery Andrade et al.(1996)31
Cohort (n=6), with and without cardiopulmonary bypass (CBP) Criteria—tachycardia, oliguria, refractory hypoperfusion to high dose
catecholamine MB 1.5 mg/kg/1 hr Results: restoration of blood pressure; pre-MB vs. post-MB SVR=868 vs.
1693 dyne/s/cm5; no adverse effect on CO or PVR 2b level of evidence—small cohort, limited data
Leyh et al. (2003)5
Cohort (n=54) out of 1111 cardiac surgery patients in 12 months Criteria –CO 4l/min, SVR<600 dyne/s/cm5, norepinephrine 0.5 mcg/kg/min MB 2mg/kg/20 min Results (0 hr vs. 1hr vs. 6hrs vs. 12 hrs):
MAP 68 vs. 72 vs. 73, (p<0.02) CO 7.6 vs. 6.5 vs. 5.8, (p<0.001) SVR 547 vs. 766 vs. 876, (p<0.001) 4/54 (7.4%) no response to treatment 3/54 (5.6%) mortality rate—2/4 nonresponders)
2b level of evidence—wide range of cardiac surgical procedures, no control group, 76% male patients
MB: Cardiac Surgery Levin et al. (2004)6
Cohort progressing to PRCT (n=56) out of 638 cardiac surgery patients in 5 months
Criteria—MAP<50 mmHg, CVP<5 mmHg, PCWP<10mmHg, CI=2.5 l/min/m3, SVR<800 dyne/s/cm5, vasopressor requirement
MB 1.5 mg/kg/1 hr vs. placebo Results: MB VS vs. Placebo VS
Duration of VS: less than 2 hrs vs. up to 48 hrs (p<0.0007)
Vasopressor requirement: at 2 hrs (p<0.002); at 3, 6, 12, 24 hrs postop (p<0.00)
Renal failure, respiratory failure, myopathy: 2 vs. 8, (p<0.03) Sepsis and MODS: 0 vs. 7, (p<0.005) Mortality:
0% vs. 21.4%, (p<0.01) 1b level of evidence—small numbers progressing to RCT with patients from
4 centers, questionable random assignment due to uneven distribution of patients in different hospitals (2,9,14, 31)
MB: Cardiac Surgery Ozar et al. (2005)7
PRCT (n=100), high VS risk patients divided equally in MB and placebo group Criteria—MAP<50 mmHg, CVP<5 mmHg, PCWP<10mmHg, CI=2.5 l/min/m3,
SVR<800 dyne/s/cm5, norepinephrine requirement 0.5 mcg/kg/min MB 2 mg/kg/30 min 1 hr preoperatively Results: MB vs. Placebo
Incidence of VS: 0 vs. 13 (p<0.001)
Progress of VS: 6 placebo patients had refractory to norepinephrine VS (p<0.001) 4/6 resolved in up to 8 hours, 2/6 died of MSOF
SVR on CBP significantly higher in MB group (p<0.001) Norepinephrine requirement:
To keep MAP on CBP >45: 4% vs. 82 % Required NE 0.5 mcg/kg/min (p<0.001)
Fluid Requirement on CBP: Crystalloid (p=0.024) Colloid (p=0.027) RBC (p<0.001)
Length of stay: ICU: 1.2 vs. 2.1, (p<0.001) Hospital 6.1 vs. 8.4, (p<0.001)
1b level of evidence
ConclusionMB is a novel therapeutic option for
patients with VSDespite the abundance of case reports on
the use of MB as a rescue drug there are limited number of cohort/RCTs evaluating the use of the drug
Further large studies should be performed before MB can be recommended as a first line therapy.
References:1. Gomes et al. Vasoplegic syndrome: a new dilemma. J Thorac Cardiovasc Surg 1194. 2. Gomes et al. Vasoplegic syndrome after off-pump coronary artery bypass surgery. Eur J
Cardiothorac Surg 2003. 3. Ulusoy HB, Gul H, Seyrek M, Yildiz O, Ulku C, Yildirim V, et al. The concentration-
dependent contractile effect of methylene blue in the human internal mammary artery: a quantitative approach to its use in the vasoplegic syndrome. J Cardiothorac Vasc Anesth. 2008; 22(4): 560-4.
4. Mekontso-Dessap A, Houel R, Soustelle C, Kirsch M, Thebert D, Loisance DY. Risk factors
for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001;71:1428-1432.
5. Leyh RG, Kofidis T, Strüber M, Fischer S, Knobloch K, Wachsmann B, et al. Methylene
blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg. 2003; 125(6): 1426-31.
6. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, et al. Methylene
blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004; 77(2): 496-9.
7. Ozal E, Kuralay E, Yildirim V, Kilic S, Bolcal C, Kücükarslan N, et al. Preoperative
methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg. 2005; 79(5): 1615-9.
8. 10. Evora PR, Levin RL. Methylene blue as drug of choice for cate- cholamine-refractory vasoplegia after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2004; 127: 895-896 .
9. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomised, controlled study. Crit Care Med 2001; 29: 1860-1867
10.Kwok ES, Howes D. Use of methylene blue in sepsis: a systematic review. J Intensive Care Med 2006; 21: 359-363
11.Evora PR, Oliveira Neto AM, Duarte NM, Vicente WV. Methylene blue as treatment for contrast medium-induced anaphylaxis. J Postgrad Med 2002; 48: 327-328.
12.Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene
blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000; 82: 291-294.
13.Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat refractory
hypotension in septic endocarditis. J Thorac Cardiovasc Surg 2003; 125: 426-427 14.Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic
effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg 2006; 103: 2-8 .
15.Mathew S, Linhartova L, Raghuraman G. Hyperpyrexia and pro- longed postoperative disorientation following methylene blue infusion during parathyroidectomy. Anaesthesia 2006; 61: 580- 583.
16.Vutskits L, Briner A, Klauser P, et al. Adverse effects of methylene blue on central nervous
system. Anesthesiology 2008; 108: 684- 692.
17.Burrows GE. Methylene blue: effects and disposition in sheep. J Vet Pharmacol Ther 1984; 7: 225-231
18.Zhang H, Rogiers P, Preiser JC, et al. Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock. Crit Care Med 1995; 23: 1711-1721
19.Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide syn- thesis by methylene blue.
Biochem Pharmacol 1993; 45: 367- 374. 20. Mayer B, Brunner F, Schmidt K. Novel actions of methylene blue. Eur Heart J 1993; 14;
Suppl I: 22-26. 21. Martin W,Villani GM, Jothianandan D, Furchgott RF. Selective blockade of endothelium-
dependent and glyceryl trinitrate- induced relaxation by hemoglobin and by methylene blue in rabbit aorta. J Pharmacol Exp Ther 1985; 232: 708-716.
22. Tsai SC, Adamik R, Manganiello VC, Vaughan M. Regulation of activity of purified
guanylate cyclase from liver that is unresponsive to nitric oxide. Biochem J 1983; 215: 447-455
23.Schneider F, Luton PH, Hasselmann M, et al. Methylene blue increases systemic vascular resistance in human septic shock. Intensive Care Med 1992; 9: 309-311.
24.Schneider F, Bucher B, Schott C, Andre A, Julou-Schaeffer G, Stoclet JC. Effect of bacterial
lipopolysaccharide on function of rat small femoral arteries. Am J Physiol 1994; 266: H191-198
25.Schenk P, Madl C, Rezaie-Majd S, Lehr S, Muller C. Methylene blue improves the hepatopulmonary syndrome. Ann Inten Med 2000; 133: 701-706.
26.Kalambokis G, Economou M, Fotopouslos A, Bokharhii JA, Christos P, Paraskevi K, Kontanstinos P, Katsaraki A, Tsinas EV. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites. Dig Liver Dis 2003; 50:1771-1777.
27. Almeida JA, Riordan SM, Liu J, Galhenage S, Kim R, Bihari D, Wegner EA,
Cranney GB, Thomas PS. Deleterious effects of nitric oxide inhibition in chronic hepatopulmonary syndrome. Eur J Gastroenterol Hepatol.2007;19:34-134.6.
28.Peer G, Itzhakov E, Wollman Y, Chernihovsky T, Grosskopf I, Segev D, Silverberg D, Blum
M, Schwartz D, Iaina A. Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension. Nephrol Dial Transplant 2001; 16:14361441.
29. Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, van Kamp GJ, Bronsveld W, Thijs LG.
Methylene blue increases myocardial function in septic shock. Crit Care Med 1995;23:1363–70.
30.Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care 2002;30:755–62.
31.Andrade JCS, Batista Filho ML, Evora PRB, Tavares JR, Buffolo E, Ribeiro EE, Silva LA,
Teles CA, Petrizzo A, Barata F, Vitor V, Duprat R. Methylene blue administration in the treatment of the vasoplegic syndrome after cardiac surgery. Revista Brasileira de Cirurgia Cardiovascular (Rev Bras Cir Cardiovasc) 1996;11:107-114.